异基因干细胞移植后完全缓解期间罕见复发起始干细胞的识别与监测
该回顾性研究对异基因干细胞移植后完全缓解的骨髓样本联合流式细胞分选与突变筛查,检测罕见复发起始干细胞的持续存在。15例后续复发患者的25份完全缓解样本中,仅9份单核细胞MRD阳性,而分选造血干/祖细胞全部MRD阳性且变异等位基因频率更高;13例长期持续完全缓解患者造血干/祖细胞保持MRD阴性。
要点
- 15例后续复发患者25份完全缓解样本中,单核细胞仅9份MRD阳性,分选造血干/祖细胞全部MRD阳性。
- 造血干/祖细胞变异等位基因频率较单核细胞平均高97倍,且在连续样本中先于单核细胞出现MRD阳性。
- 13例长期持续完全缓解患者造血干/祖细胞保持MRD阴性。
核心结论
- 识别复发起始肿瘤干细胞并对其持续存在进行突变MRD筛查,可一致地提高异基因干细胞移植后MRD敏感性并更早预测复发。
研究设计与样本
- 回顾性研究,纳入异基因干细胞移植后复发及持续完全缓解的骨髓增生异常综合征及相关髓系恶性肿瘤患者。
- 在移植后多个完全缓解时间点采集骨髓,联合流式细胞分选与突变筛查检测罕见复发起始干细胞的持续存在。
主要发现
- 15例后续复发患者的25份完全缓解样本中,仅9份单核细胞MRD阳性,而流式分选造血干/祖细胞全部MRD阳性。
- 造血干/祖细胞变异等位基因频率始终高于单核细胞,平均高97倍。
- 多个连续样本中造血干/祖细胞MRD阳性先于单核细胞,部分病例先于复发超过2年。
- 13例长期持续完全缓解患者造血干/祖细胞保持MRD阴性。
- 总CD34+细胞亦显示MRD敏感性增强,但造血干/祖细胞克隆受累始终更高,平均高8倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse after complete remission (CR) remains the main cause of mortality after allogeneic stem cell transplantation for hematological malignancies and, therefore, improved biomarkers for early prediction of relapse remains a critical goal toward development and assessment of preemptive relapse treatment. Because the significance of cancer stem cells as a source of relapses remains unclear, we investigated whether mutational screening for persistence of rare cancer stem cells would enhance measurable residual disease (MRD) and early relapse prediction after transplantation. In a retrospective study of patients who relapsed and patients who achieved continuous-CR with myelodysplastic syndromes and related myeloid malignancies, combined flow cytometric cell sorting and mutational screening for persistence of rare relapse-initiating stem cells was performed in the bone marrow at multiple CR time points after transplantation. In 25 CR samples from 15 patients that later relapsed, only 9 samples were MRD-positive in mononuclear cells (MNCs) whereas flowcytometric-sorted hematopoietic stem and progenitor cells (HSPCs) were MRD-positive in all samples, and always with a higher variant allele frequency than in MNCs (mean, 97-fold). MRD-positivity in HSPCs preceded MNCs in multiple sequential samples, in some cases preceding relapse by >2 years. In contrast, in 13 patients in long-term continuous-CR, HSPCs remained MRD-negative. Enhanced MRD sensitivity was also observed in total CD34+ cells, but HSPCs were always more clonally involved (mean, 8-fold). In conclusion, identification of relapse-initiating cancer stem cells and mutational MRD screening for their persistence consistently enhances MRD sensitivity and earlier prediction of relapse after allogeneic stem cell transplantation.
引用
- Dimitriou M, Mortera-Blanco T, Tobiasson M, et al. Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation. Blood. 2024. PMID: 38096358. doi:10.1182/blood.2023022851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。